Jennifer Brown, MD
Family Medicine · Midlothian, VANPI 1164473179
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 567 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 52 manufacturers reported payments, led by AbbVie at 31.5% of the total. Among family medicine clinicians in VA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 567 payments — averaging $15.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$3K
- Lilly USA, LLC$692
- Amgen$487
- Novo Nordisk$472
- Boehringer Ingelheim$416
- Pfizer$382
- plus $3K from 46 others
Across 16 payments — averaging $81,010 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Regeneron$1.3M
What the payments were for
- Food & beverage$8,527100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
How this compares
$8,527 in reported general payments places this provider in the 90th percentile of 2,553 family medicine providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 41 | $41,663 |
| EliquisApixaban | 30 | $35,920 |
| FarxigaDapagliflozin Propanediol | 45 | $33,402 |
| TrulicityDulaglutide | 27 | $25,463 |
| JardianceEmpagliflozin | 12 | $19,265 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 14 | $14,353 |
| Repatha SureclickEvolocumab | 16 | $12,961 |
| XareltoRivaroxaban | 17 | $12,508 |
| PaxlovidNirmatrelvir/Ritonavir | 18 | $5,655 |
| Breo ElliptaFluticasone/Vilanterol | 11 | $5,442 |
| Rosuvastatin Calcium | 167 | $2,429 |
| SynthroidLevothyroxine Sodium | 45 | $2,377 |
| Metoprolol Succinate | 127 | $2,282 |
| Levothyroxine Sodium | 303 | $2,235 |
| Duloxetine Hcl | 63 | $2,127 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $472 | $41,66341 claims |
| PfizerEliquis, Paxlovid | $382 | $41,57548 claims |
| AstraZenecaFarxiga | $351 | $33,40245 claims |
| Lilly USA, LLCTrulicity | $692 | $25,46327 claims |
| Boehringer IngelheimJardiance | $416 | $19,26512 claims |
| Johnson & JohnsonXarelto | $85 | $12,50817 claims |
| GSKBreo Ellipta | $198 | $5,44211 claims |
| AbbVieSynthroid | $2,685 | $2,37745 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $63 | $2,235303 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,553 family medicine providers in Virginia.
Other family medicine in Midlothian
- Donald SandersMidlothian$15K
- Oluwaronke AwosikaFort Gregg Adams$397K
- Monique MatuskowitzNorfolk$110K
- Paul StairsRichmond$105K
- Edwin RobinsonRichmond$83K
- Benjamin PhilpottRocky Mount$64K
- John MolaiyArlington$64K
- Catherine VarneyZion Crossroads$47K
- Jordan TranWinchester$42K
- John ClayColonial Heights$40K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.